Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease

The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.

Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis.

Researchers from the National Institute on Aging (NIA), NIH, have developed methods for the generation of tBregs, and for using tBregs to produce Tregs, and methods that inactivate or deplete tBregs. These methods have significant therapeutic value in the combat with cancer immune escape and metastasis, and in the control of harmful autoimmune diseases.

Potential Commercial Applications: Competitive Advantages:
  • Production of cellular cancer vaccines
  • Treatments for immune-mediated disorders
  • Treatments for cancer
  • Treatments for chronic viral infections

Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
  • In situ data available
  • Ex vivo data available


Bira Arya (NIA)  ➽ more inventions...

Purevdorj Olkhanud (NIA)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,228,171 issued 2016-01-05
US Application No. 61/302,074
US Application No. 13/577,226
PCT Application No. PCT/US2011/023789

Collaboration Opportunity:

The Immunotherapeutics Unit, National Institute on Aging, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the utilization of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape. Please contact Nicole Darack, Ph.D. at 240-276-5493 or for more information. Click here to view the NCI collaborative opportunity announcement.

Licensing Contact:
Charlotte McGuinness, Ph.D., J.D.
Phone: 240-276-5530

OTT Reference No: E-101-2010/0
Updated: Sep 21, 2015